Recro Pharma, Inc. (REPH) financial statements (2021 and earlier)

Company profile

Business Address 490 LAPP ROAD
MALVERN, PA 19355
State of Incorp. PA
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments19383258393749
Cash and cash equivalents19383046393649
Short-term investments  212 1 
Receivables14161816131212
Inventory, net of allowances, customer advances and progress billings1513101011108
Inventory1513101011108
Contract with customer, asset91185577
Other undisclosed current assets3465433
Total current assets:60827395717079
Noncurrent Assets
Operating lease, right-of-use asset01  
Property, plant and equipment42484947464239
Intangible assets, net (including goodwill)8373738393940
Goodwill4666666
Intangible assets, net (excluding goodwill)3303132323334
Deferred tax assets, net 2523
Other undisclosed noncurrent assets  22   
Total noncurrent assets:5086888684106101
TOTAL ASSETS:110168162181155176180
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities57516191213
Accounts payable11111556
Accrued liabilities42131412
Employee-related liabilities 433 55
Deferred revenue 1  
Debt01     
Disposal group, including discontinued operation1      
Business combination, contingent consideration, liability   5103434
Other undisclosed current liabilities 235 53
Total current liabilities:610827295150
Noncurrent Liabilities
Long-term debt and lease obligation111110107106645554
Long-term debt, excluding current maturities110109107106645554
Operating lease, liability01  
Liabilities, other than long-term debt 666266815551
Business combination, contingent consideration, liability 666266815551
Other undisclosed noncurrent liabilities 232110
Total noncurrent liabilities:111177172173146111106
Total liabilities:117188181200175162156
Stockholders' equity
Stockholders' equity attributable to parent(7)(20)(19)(19)(20)1424
Common stock0000000
Additional paid in capital200177174171169160158
Accumulated other comprehensive loss   (0)   
Accumulated deficit(207)(197)(193)(190)(188)(147)(134)
Total stockholders' equity:(7)(20)(19)(19)(20)1424
TOTAL LIABILITIES AND EQUITY:110168162181155176180

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues18253125181822
Cost of revenue(14)(13)(14)(14)(13)(12)(12)
Cost of goods and services sold (11)(14)(14)(12)(8)(12)
Gross profit:41217115710
Operating expenses27(11)(17)(24)(20)(20)(23)
Other undisclosed operating income (loss)(12) 215  0
Operating income (loss):19122(14)(14)(13)
Nonoperating income (expense)
(Investment Income, Nonoperating)
(1)000000
Interest and debt expense(5)(5)(5)(4)(2)(2)(2)
Income (loss) from continuing operations before equity method investments, income taxes:13(4)(3)(2)(16)(16)(15)
Other undisclosed income from continuing operations before income taxes20      
Income (loss) from continuing operations before income taxes:33(4)(3)(2)(16)(16)(15)
Income tax expense (benefit)    (25)23
Other undisclosed loss from continuing operations(1)      
Income (loss) from continuing operations:32(4)(3)(2)(41)(13)(13)
Other undisclosed loss before gain (loss) on sale of properties(23)      
Income (loss) before gain (loss) on sale of properties:8(4)(3)(2)(41)(13)(13)
Other undisclosed net loss(18)      
Net loss available to common stockholders, basic:(10)(4)(3)(2)(41)(13)(13)
Dilutive securities, effect on basic earnings per share   (0)   
Net loss available to common stockholders, diluted:(10)(4)(3)(2)(41)(13)(13)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(10)(4)(3)(2)(41)(13)(13)
Other comprehensive income (loss)  (0)00  
Comprehensive loss:(10)(4)(3)(2)(41)(13)(13)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0 0(0)(0) 0
Comprehensive loss, net of tax, attributable to parent:(10)(4)(3)(2)(41)(13)(13)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: